Trimetazidine on Ischemic Injury and Reperfusion in Coronary Artery Bypass Grafting;Trimetazidina na injúria de isquemia e reperfusão em cirurgia de revascularização do miocárdio

Arquivos Brasileiros de Cardiologia

Volumn 97, Issue 3, 2011, Pages 209-216

  Martins, Gerez Fernandes ^a   de Siqueira Filho, Aristarco Gonçalves ^b   de Figueiredo Santos, João Bosco ^a   Assunção, Claudio Roberto Cavalcanti ^a   Bottino, Francisca ^a   de Carvalho, Káttia Gerúndio ^a   Valência, Alberto ^a  

^a Instituto Estadual de Cardiologia Aloysio de Castro   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Dosage; Myocardial ischemia; Myocardial reperfusion; Myocardial revascularization; Trimetazidine administration

Indexed keywords

BIOLOGICAL MARKER; CREATINE KINASE MB; PLACEBO; TRIMETAZIDINE; TROPONIN T;

AORTA SURGERY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY;

BIOLOGICAL MARKERS; CORONARY ARTERY BYPASS; CREATINE KINASE, MB FORM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PLACEBO EFFECT; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TRIMETAZIDINE; TROPONIN T; VASODILATOR AGENTS;

EID: 82455198743     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2011005000079     Document Type: Article

References (40)

1. Artigou JY, Chamiot JC, Bonnefont-Rousselot D, Salloum J, Grosgogeat Y. Le traitement antioxydant dans lìschemie reperfusion myocardique. Arch Mal Couer Vaiss. 1993;86(4):105-9.
2. Brasileiro ALS. A injúria de reperfusão miocárdica. Rev Socerj. 1997;10(2):79-88.
3. Malbouisson SML, Santos ML, Auler Jr JO, Carmona MJC. Proteção miocárdica em cirurgia cardíaca. Rev Bras Anestesiol. 2005;55(5):558-74.
4. Iskesen I, Saribulbul O, Cerrahoglu M, Var A, Nazli Y, Sirin H. Trimetazidine reduces oxidative stress in cardiac surgery. Circ J. 2006;70(9):1169-73.
5. Parang P, Singh B, Arora R. Metabolic modulators for chronic cardiac ischemia. J Cardiovasc Pharmacol Ther. 2005;10(4):217-23.
6. Wolff A, Rotmensch HH, Stanley WC, Ferrari R. Metabolic approaches to the treatment of ischemic heart disease: the clinician ́s perspective. Heart Fail Rev. 2002;7(2):187-203.
7. Turnerir B, Çolak O, Alatas O, Besogul Y, Kural T, Aslan R. Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann Thorac Surg. 1999;68(6):2173-6.
8. Tepliakov AT, Dzhavadova GK, Akhemedov SD, Vecherski and #x012D; II, Vesnina ZV. Effect of trimetazidine on regressione of ischemic dysfunction of myocardium after coronary bypass surgery on beating heart. Kardiologiia. 2004;44(4):51-6.
9. Gonzales-Bertomeu V, Mosquera-Bougas A, Kaski CJ. Role of trimetazidine in management of ischeamic cardiomyopathy. Am J Cardiol. 2006;98(5A):19J-24J.
10. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27(11):1341-81.
11. Babuin L, Jaffe SA. Troponin: the biomarker of choice for detection of cardiac injury. Clin Chem. 2001;47(3):1191-200.
12. Lang MR, Bierig M, Devereux BR, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440-63.
13. Cohen J. Statistical power analysis for the behavior sciences. New York: Academic Press; 1969.
14. Cerqueira DM, Weissman JN, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. Circulation. 2002;105(4):539-42.
15. Mair J, Dienstl F, Puschendorf B. Cardiac troponin T in the diagnosis of myocardial injury. Crit Rev Clin Lab Sci. 1992;29(1):31-57.
16. Bolli R, Marbán E. Molecular and celular mechanisms of myocardial stunning. Physiol Rev. 1999;79(2):609-34.
17. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfuncion. Circulation. 1982;66(6):1146-9.
18. Vendrinne JM, Vendrinne C, Bompard D, Lehot JJ, Boissel JP, Champsaur G, et al. Myocardial protection during coronary artery bypass graft surgery: a randomized, double-blind, placebo-controlled study with trimetazidine. Anesth Analg. 1996;82(4):712-8.
19. Proheas Martinez J, Anello Utrera H, Gonzalez-Fernandez J, Rodrigues de Armas L. Índice de Tei, nuevo indicador Doppler para el estúdio de la insuficiência cardíaca. Rev Cubana Méd. 2004;43(4):1-7.
20. Fabiani JN, Ponzio O, Emerit I, Massonet-Castel S, Paris M, Chevalier P, et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg. 1992;33(4):486-91.
21. Napoli DP, Tacardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart. 2005;91:161-5.
22. Lopatin IUM, Dronova EP. Clinical-pharmacoeconomic aspects of trimetazidine modified release use in patients with ischemic heart disease undergoing coronary artery bypass grafting. Kardiologiia. 2009;49(2):15-21.
23. Cesar LAM, Mansur AP, Armaganyan D, Ameno JG; Sociedade Brasileira de Cardiologia. Diretriz de angina estável. Arq Bras Cardiol. 2004;83(supl 2):1-43.
24. Rosano MCG, Vitale C, Sposato B, Mercurio G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol. 2003;2:16.
25. Chierchia LS. Trimetazidine and left ventricular ischaemic dysfuncion: an overview of clinical evidence. Eur Heart J. 2001;3(Suppl O):O16-O20.
26. César MAL, Matias Jr W, Armaganijan D, Gimenez V, Jallad S, Del Monaco MI, et al. Trimetazidine to reverse ischemia in pacients with class I or II angina: a randomized, double-blind, placebo controlled dobutamine-atropine stress echocardiography study. Coron Artery Dis. 2007;18(4):259-63.
27. Capdevila C, Portolés M, Hernandiz A, Pallares V, Cosin J. La troponina t como posible marcador del dano miocárdico menor: su aplicación en el miocárdio aturdido y en la isquemia silente. Rev Esp Cardiol. 2001;54(5):580-91.
28. Lang K, Borner A, Figulla HR. Comparison of biochemical markers for detection of minimal myocardial injury: superior sensibility of cardiac troponin-T ELISA. J Intern Med. 2000;247(1):119-23.
29. Kemp M, Donovan J, Higham H, Hooper J. Biochemical markers of myocardial injury. Br J Anaesth. 2004;93(1):63-73.
30. Bardorff MM, Hallermayer K, Schroder A, Ebert C, Borgya A, Gerhardt W, et al. Improved troponin T ELISA specific for cardiac troponin T isoform: assay development and analytical and clinical validation. Clin Chem. 1997;43(3):458-66.
31. Abramov D, Abu-Tailakh M, Frieger M, Ganiel A, Tuvbin D, Wolak A. Plasma troponin levels after cardiac surgery vs after myocardial infarction. Asian Cardiovasc Thorac Ann. 2006;14(6):530-5.
32. Carrier M, Pellerin M, Perrault PL, Solymoss BC, Pelletier LC. Troponin levels in pacients with myocardial infarction after coronary artery bypass grafting. Ann Thorac Surg. 2000;69(2):435-40.
33. Klatte K, Shaidman BR, Theroux P, Gavard JA, Stocke K, Boyce S, et al. Increase mortality after coronary artery bypass grast surgery is associated whith increased levels of postoperative creatinekinase-myocardial and band isoenzime release.(GUARDIAN trials). J Am Coll Cardiol. 2001;38(4):1070-7.
34. Costa MA, Carere RG, Lichtenstein SV, Foley DP, de Valk V, Lindenboom W, et al. Incidence, predictors and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the arterial revascularization therapies study (ARTS). Circulation. 2001;104(22):2689-93.
35. Baggish LA, MacGillivray ET, Hoffman W, Newell JB, Lewandrowski KB, Lee- Lewandrowski E, et al. Postoperative troponin-t predicts prolonged intensive care unit lenght of stay following cardiac surgery. Crit Care Med. 2004;34(9):1866-71.
36. Lehrke S, Steen H, Sievers HH, Peters H, Opitz A, Müller-Bardorff M, et al. Cardiac troponin T for prediction of short- and long-term morbidity and mortality after elective open heart surgery. Clin Chem. 2004;50(9):1560-7.
37. Renauld JF. Internal pH, Na+ and Ca2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther. 1988;1(6):677-86.
38. Argaud L, Gomes L, Gateau-Roesch O, Couture-Lepetit E, Loufouat J, Robert D, et al. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol. 2005;39(6):893-9.
39. Maridonneau-Parini I, Harpey C. Effect of trimetazidine on menbrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol. 1985;20(2):148-51.
40. Iskesen I, Kurdal AT, Eserdag M, Cerrahoglu M, Sirin BH. Trimetazidine may protect the myocardium during cardiac surgery. Heart Surg Forum. 2009;12(3):E175-9.